Rosmarinic acid ameliorated oxidative stress, neuronal injuries, and mitochondrial dysfunctions mediated by polyglutamine and ɑ-synuclein in Caenorhabditis elegans models

Mol Neurobiol. 2024 Dec;61(12):10138-10158. doi: 10.1007/s12035-024-04206-4. Epub 2024 May 4.

Abstract

Numerous natural antioxidants have been developed into agents for neurodegenerative diseases (NDs) treatment. Rosmarinic acid (RA), an excellent antioxidant, exhibits neuroprotective activity, but its anti-NDs efficacy remains puzzling. Here, Caenorhabditis elegans models were employed to systematically reveal RA-mediated mechanisms in delaying NDs from diverse facets, including oxidative stress, the homeostasis of neural and protein, and mitochondrial disorders. Firstly, RA significantly inhibited reactive oxygen species accumulation, reduced peroxide malonaldehyde production, and strengthened the antioxidant defense system via increasing superoxide dismutase activity. Besides, RA reduced neuronal loss and ameliorated polyglutamine and ɑ-synuclein-mediated dyskinesia in NDs models. Further, in combination with the data and molecular docking results, RA may bind specifically to Huntington protein and ɑ-synuclein to prevent toxic protein aggregation and thus enhance proteostasis. Finally, RA ameliorated mitochondrial dysfunction including increasing adenosine triphosphate and mitochondrial membrane potential levels and rescuing mitochondrial membrane proteins' expressions and mitochondrial structural abnormalities via regulating mitochondrial dynamics genes and improving the mitochondrial kinetic homeostasis. Thus, this study systematically revealed the RA-mediated neuroprotective mechanism and promoted RA as a promising nutritional intervention strategy to prevent NDs.

Keywords: Caenorhabditis elegans; Mitochondrial dysfunctions; Neuron damages; Oxidative stress; Proteostasis network; Rosmarinic acid.

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Antioxidants / pharmacology
  • Caenorhabditis elegans Proteins / metabolism
  • Caenorhabditis elegans* / drug effects
  • Caenorhabditis elegans* / metabolism
  • Cinnamates* / pharmacology
  • Cinnamates* / therapeutic use
  • Depsides* / pharmacology
  • Depsides* / therapeutic use
  • Disease Models, Animal*
  • Membrane Potential, Mitochondrial / drug effects
  • Mitochondria* / drug effects
  • Mitochondria* / metabolism
  • Molecular Docking Simulation
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / pathology
  • Neurons* / drug effects
  • Neurons* / metabolism
  • Neurons* / pathology
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Oxidative Stress* / drug effects
  • Peptides* / pharmacology
  • Reactive Oxygen Species / metabolism
  • Rosmarinic Acid*
  • alpha-Synuclein* / metabolism

Substances

  • Depsides
  • Rosmarinic Acid
  • polyglutamine
  • Peptides
  • Cinnamates
  • alpha-Synuclein
  • Antioxidants
  • Neuroprotective Agents
  • Reactive Oxygen Species
  • Caenorhabditis elegans Proteins